All In Biotech

Drug Trial Radar · NCT03699124

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Last checked: Nov 19, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,129

Actual

Start

Jun 19, 2019

Primary completion

Jan 6, 2020

Study completion Jun 22, 2020

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Oct 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 3 multicenter trial to evaluate safety and immune response of three consecutive production lots of freeze-dried (FD) MVA-BN smallpox vaccine. The vaccine will be given to healthy subjects who do not have a smallpox scar. Approximately 1110 subjects will be randomly enrolled into one of three groups: Group 1 will include 370 subjects, who will receive two separate injections (shot) with a short needle, given below the skin of the upper arm with 0.5 mL FD MVA-BN (Lot 1). Group 2 will include 370 subjects, who will receive two separate injections (shot) with a short needle, given below the skin of the upper arm with 0.5 mL FD MVA-BN (Lot 2). Group 3 will include 370 subjects, who will receive two separate injections (shot) with a short needle, given below the skin of the upper arm with 0.5 mL FD MVA-BN (Lot 3). The primary objective of the trial is to show that the immune response elicited (produced) by three consecutively produced MVA-BN lots are statistically (numerically) comparable.

Conditions

  • Smallpox

Interventions

  • FD MVA-BNBiological

    Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vaccinia-Specific Neutralizing Antibodies Measured by Plaque Reduction Neutralization Test (PRNT)Time frame: Two weeks post second vaccination; approximately Week 6.

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Optimal Research, LLC (Synexus)

    Melbourne, Florida

  • Optimal Research, LLC (Synexus)

    Peoria, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kentucky Healthcare Chandler Hospital

    Lexington, Kentucky

  • Optimal Research, LLC (Synexus)

    Rockville, Maryland

  • Saint Louis University

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • M3 Wake Research, Inc.

    Raleigh, North Carolina

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Omega Medical Research

    Warwick, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.